Bacillus cereus is one of nature’s most resilient opportunists. A Gram-positive, rod-shaped bacterium that lives in soil, dust and on plant surfaces, it slips easily into raw milk during collection and processing. Its true weapon is the endospore, a dormant, tough-coated structure that shrugs off boiling, pasteurization and many chemical sanitizers. When conditions improve — in a carton of chilled milk, a vat of reconstituted powdered milk, or a damp corner of a processing line — the spores germinate into actively dividing cells. Some strains produce cereulide, a heat-stable toxin that causes vomiting and survives cooking; others secrete enterotoxins that trigger diarrheal illness. The bacterium also builds biofilms, slimy microbial fortresses on stainless steel and rubber seals that continuously seed contamination into passing products. To make matters worse, the Isfahan team’s survey of one hundred B. cereus isolates recovered from various food sources revealed alarming resistance profiles, with 97 percent of the isolates resistant to gentamicin — the highest resistance recorded among the antibiotics tested — underscoring why alternatives are urgently needed.

The answer the researchers found is elegantly simple: a bigger, faster hunter. CM1 belongs to the class Caudoviricetes, the enormous group of tailed, double-stranded DNA bacteriophages that dominate the oceans, soils and, increasingly, food laboratories. Under transmission electron microscopy, the phage revealed classic tailed-phage architecture: an icosahedral protein head measuring 48 ± 2 nanometers in diameter, attached to a slender tail 142 ± 3 nanometers long. In tailed phages, the tail is more than an appendage; it is a molecular syringe and lock-pick in one. Its fiber proteins recognize specific receptors on the bacterial surface, and once a secure grip is established, the phage drives an internal channel through the cell wall and injects its genome, effectively turning the bacterium into a virus factory. The dimensions and morphology captured by the Iranian team place CM1 firmly within this lineage, while its genome sequence marks it as a species new to science.

Before any virus can be used in food, it must survive the journey, and this is where CM1’s personality becomes clear. The team subjected the phage to a battery of environmental stress tests. Its infectivity faltered at pH values above 10 and also near pH 6, indicating a preference for neutral-to-alkaline conditions. Temperature profiling identified 30 degrees Celsius as the optimum, with viral titers declining both below and above this point. Salt told a similar story of gradual attrition: as sodium chloride concentrations rose from 1 percent to a punishing 35 percent, the phage titer decreased step by step. These parameters matter enormously in practice. Dairy processing involves refrigeration, heat treatments, brines and aggressive alkaline cleaning cycles, and a biocontrol agent must retain enough infectivity at the point of application to do its job. Encouragingly, as the food challenge test would later show, CM1 remained potent enough in real milk to deliver a significant blow to B. cereus — a sign that formulation and dosing can be tuned to fit its stability window.

The phage’s infection kinetics reveal an efficient predator. The researchers determined that the optimal multiplicity of infection — the ratio of virus particles to bacterial cells at the start of an experiment — is 1, meaning one phage per bacterium is enough to achieve maximum killing without wasting viral particles, an economically attractive trait for industrial use. Adsorption assays showed that 88.7 percent of phages had attached to host cells within just 35 minutes. Adsorption is the first, decisive step of the phage life cycle: reversible contact between tail fibers and the bacterial surface quickly matures into irreversible binding, followed by genome ejection into the cell. A fast, high-percentage adsorption rate means CM1 finds and disables its victims quickly, an important property in a food matrix where bacteria may be suspended in liquid, embedded in biofilms, or hiding in microscopic crevices. One-step growth experiments completed the kinetic portrait, allowing the team to map the rhythm of replication and release that underlies the phage’s killing power.

Perhaps CM1’s most marketable quality is its pickiness. When the researchers challenged the phage with a panel of different bacterial species alongside B. cereus isolates derived from food samples, the virus proved specific to B. cereus and demonstrated lytic activity against 69 percent of those isolates. Efficiency-of-plating analyses quantified how vigorously the phage grew on each susceptible strain. In medicine and food production alike, such specificity is a double-edged sword, but here the edges cut favorably. A virus that attacks only B. cereus will not disturb beneficial microbes, starter cultures or the wider food microbiota, a precision no broad-spectrum antibiotic or chemical disinfectant can match. At the same time, the fact that roughly a third of isolates resisted infection is a sobering reminder that no single phage is a silver bullet; commercial biocontrol typically relies on phage cocktails whose combined host ranges overlap to close the gaps.

The phage’s genome tells a reassuring story. Whole-genome sequencing revealed a double-stranded DNA molecule of 156,598 base pairs with a GC content of 39.7 percent. Bioinformatic screening of the sequence found no antimicrobial resistance genes and no virulence factors — a critical safety criterion, because a phage used in food must never act as a vehicle that ferries dangerous genes between bacteria. Nor does CM1 carry the toolkit of a temperate virus: it is strictly lytic, killing its host outright rather than integrating quietly into the bacterial genome, which is exactly the behavior desired in a biocontrol agent. Among the annotated genes, the tail-associated proteins carried domains related to depolymerases and lysins, two classes of enzymes with starring roles in phage attack. Depolymerases degrade the polysaccharide coatings and extracellular matrices that bacteria build around themselves, clearing a path for the virus to reach its receptor; lysins cleave peptidoglycan, the rigid mesh of the bacterial cell wall, from within during the final explosive step of replication.

Those very enzymes likely explain one of the study’s most practically important results: CM1 significantly reduced the biofilm biomass produced by B. cereus. Biofilms are the fortified cities of the microbial world — cells encased in a self-made matrix of polysaccharides, proteins and DNA that clings to surfaces and resists disinfectants at concentrations far above those that kill free-swimming bacteria. In dairy plants, B. cereus biofilms on pipes, valves and gaskets act as chronic contamination reservoirs, and because the bacterium also forms heat-resistant spores, even rigorous sanitation regimens rarely eliminate it completely. A phage armed with matrix-degrading depolymerases can do what chemical sanitizers struggle to accomplish: penetrate the biofilm’s protective sludge, reach the embedded cells, and dismantle the colony from the inside. For an industry haunted by product recalls and shelf-life losses attributable to B. cereus and its relatives, that capability alone makes CM1 worth serious attention.

The decisive experiment, however, took place in the product itself. In the food challenge test, milk was inoculated with B. cereus, and treatment groups received the mixture of bacterium and phage. The outcome was statistically unambiguous: the titer of B. cereus — the number of viable bacteria — was significantly decreased in the groups that received the phage, with a probability value below 0.05. In plain terms, adding CM1 measurably suppressed the pathogen in a real food matrix, not just in laboratory broth. This matters because milk is a demanding environment for phages: it is nutrient-rich but carries its own pH, fat and protein chemistry, and the study’s stability data showed that conditions near pH 6 can affect CM1’s infectivity. The fact that the phage still delivered a significant kill in milk suggests that, with proper dosing and timing, CM1 can overcome these barriers — a prerequisite for any future application in liquid milk processing or in the production of powdered milk, one of the commodities most vulnerable to B. cereus contamination.

CM1 arrives at a moment when phage biocontrol is moving from laboratory curiosity toward commercial reality, with phage products already approved in some jurisdictions for decontaminating food. Its credentials are strong: activity against the majority of B. cereus isolates tested, rapid adsorption, an economical optimal multiplicity of infection, demonstrable anti-biofilm power, a genome stripped of resistance and virulence genes, and proven efficacy in milk itself. The authors conclude that, given this combination of favorable properties, Bacillus phage CM1 is a promising and safe candidate biocontrol agent against B. cereus in food-related settings. The road from bench to dairy plant still requires larger trials, stable formulations that respect the phage’s temperature and salt sensitivities, combinations with complementary phages to widen coverage, and regulatory approval. But the underlying logic is compelling. Against a pathogen that hides in spores, fortifies itself in biofilms and shrugs off gentamicin in nearly every isolate tested, science has found an adversary with a 48-nanometer head, a 142-nanometer tail, and 156,598 base pairs of pure predatory intent. The milk industry, it seems, has just acquired a microscopic new ally.

Bacteriophages, often referred to as phages, are viruses that specifically infect bacteria. Their specificity makes them an attractive candidate for food safety applications, as they can target pathogens without disrupting beneficial bacterial communities. The study’s authors embarked on the journey to isolate novel Clostridium perfringens phages from environmental sources. Through meticulous laboratory techniques, they uncovered phages capable of lysing this formidable bacteria, which poses a risk not just to consumers but also has significant economic implications for poultry farmers.

The characterization of the isolated phages provided critical insights into their structure and behavior. The researchers employed various molecular techniques to determine the genetic makeup of these phages, alongside their lytic capabilities. Understanding the life cycle of these phages is crucial, as it sheds light on how they can be effectively utilized as biocontrol agents. Bacteriophages operate by attaching to bacterial cells, injecting their genetic material, and subsequently triggering the bacterial cell’s demise. This biological warfare offers a promising avenue toward reducing pathogenic loads in food products.

In laboratory experiments, the efficacy of the isolated phages was put to the test against Clostridium perfringens strains commonly found in chicken. The results were promising, evidencing a significant reduction in bacterial counts when the phages were applied to contaminated meat samples. These findings are particularly important not only for consumer safety but also for the poultry industry, which consistently seeks strategies to enhance meat safety and quality. The ability of these phages to reduce pathogen levels suggests a viable alternative to traditional chemical preservatives and antibiotics.

As antibiotic resistance becomes a more pressing concern, the need for alternative solutions has never been greater. Phage therapy is positioned as a sustainable and environmentally friendly option that could complement or even replace existing methods of pathogen control. The study’s authors emphasized that employing phages in food safety protocols could lessen the reliance on antibiotics, curbing the increase of resistant bacterial strains that threaten both human and animal health.

The research further highlights the significance of understanding the interaction between phages and their bacterial hosts. It opens up new avenues for developing phage cocktails tailored to combat specific strains of Clostridium perfringens found in various species of poultry. By customizing treatments, food producers can ensure a comprehensive approach to pathogen management: targeting a wide array of bacterial strains while minimizing collateral damage to beneficial microbiota.

In addition to their direct antimicrobial properties, the study points out the potential prebiotic effects of phages, which could assist in promoting a healthier gut microbiome. This aspect is gaining recognition as more research uncovers the complex relationships between our health, the food we consume, and the gut microorganisms that aid in digestion and overall well-being. By enhancing healthy bacterial populations, phages could contribute not just to food safety but to the broader scope of public health.

Challenges remain in the production and application of phages in real-world settings. Identifying appropriate delivery methods that maintain the phage’s viability until consumption is paramount. The findings from this research pave the way for further investigation into harnessing these viral agents effectively, including exploring different formulations and treatment protocols that could be viable for commercial use in the poultry industry.

Future studies could also delve deeper into how environmental factors such as temperature, pH, and the presence of competing microbiota impact phage activity. Understanding these dynamics will be essential in creating robust phage-based interventions that poultry producers can implement confidently.

The implications of such research extend beyond poultry products to a wider context of food safety across various sectors. As pathogens continue to adapt and develop resistance strategies, the need for innovative biocontrol solutions becomes increasingly evident. The findings presented by Zuikarnain et al. represent a promising leap towards integrating science with practical applications that ensure public health while supporting the sustainability of food systems.

This study offers a beacon of hope in the ongoing battle against foodborne diseases, particularly in contexts where conventional methods fall short. As researchers continue to explore the potential of bacteriophages, it may not be long before they become invaluable partners in ensuring safe meat consumption, benefiting consumers, producers, and public health at large.

The integration of these tools into food safety protocols is a crucial effort needed to address the current challenges in foodborne illness management. As the research demonstrates, with the right application and understanding, bacteriophages could very well be the future of pathogen control in the food industry, answering a significant call for innovative, effective, and sustainable solutions to protect consumers and improve food safety standards globally.

Subject of Research: Bacteriophages targeting Clostridium perfringens for poultry safety.

Article Title: Isolation, characterisation, and biocontrol application of novel Clostridium perfringens phages on chicken meat.

Article References:

Zuikarnain, M.Z., Asrore, M.S.M., Yusof, M.T. et al. Isolation, characterisation, and biocontrol application of novel Clostridium perfringens phages on chicken meat.
Int Microbiol (2026). https://doi.org/10.1007/s10123-025-00759-z

Image Credits: AI Generated

DOI: 05 January 2026

Keywords: Clostridium perfringens, bacteriophages, food safety, biocontrol, poultry, antibiotic resistance, phage therapy.

Bacteriophages, viruses that specifically infect bacteria, have long been regarded as natural enemies of bacterial pathogens, offering a potential alternative to antibiotics amid rising antimicrobial resistance. The novel research executed by Jung, Y., Kim, J., Lee, JH., and their colleagues introduces previously unexplored complexity: these phage entities, JEP7 and PBC2, when introduced into mammalian systems, initiate distinct cytokine responses. Cytokines are crucial signaling proteins that orchestrate immune defense mechanisms, inflammation, and tissue repair, and the implication that phages themselves might trigger such responses unveils new dimensions for therapeutic innovation.

The study meticulously evaluated the interaction between these two bacteriophages and foodborne pathogens, confirming their potent antibacterial activity. Both JEP7 and PBC2 demonstrated specificity in lysing harmful bacteria typically implicated in food contamination, such as Salmonella and Escherichia coli strains. This specificity underscores their value as precision antimicrobials that can diminish bacterial burden without disturbing beneficial microbiota—a striking advantage over broad-spectrum antibiotics.

What sets this research apart is the detailed investigation of mammalian cellular responses to phage exposure. Utilizing cultured mammalian immune cells, the researchers monitored changes in cytokine profiles upon phage administration. They observed that JEP7 and PBC2 facilitated the secretion of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β, which are essential in mounting effective innate immune responses. Simultaneously, regulatory cytokines were also modulated, suggesting a nuanced immune balancing act rather than a simple inflammatory trigger.

Such findings challenge the traditional view that bacteriophages are passive players within higher organisms, instead positioning them as active participants in immune modulation. This immune interplay might have implications far beyond antibacterial therapy. For instance, phages could potentially be leveraged to prime the immune system against infections or even cancer, reigniting interest in phage therapy as a multifaceted biomedical tool.

Furthermore, the research illuminated the molecular mechanisms underlying the cytokine responses. Through advanced transcriptomic analyses, the researchers identified signaling pathways and receptor interactions activated upon phage exposure. Toll-like receptors (TLRs), known sentinels in pathogen recognition, appeared to mediate much of this cytokine induction. This insight bridges bacteriophage biology with mammalian innate immunity, revealing evolutionary intersections that could be exploited for therapeutic gain.

Safety concerns are paramount when considering any bacteriophage application in human health, and the study addressed this with rigorous cytotoxicity assays. Notably, neither JEP7 nor PBC2 induced harmful effects on mammalian cell viability at therapeutically relevant concentrations, thus supporting their feasibility as safe immunomodulatory agents. Moreover, their inability to replicate within mammalian cells alleviates fears of unintended viral propagation or genotoxicity.

The potential applications stemming from these findings extend into food safety regulations and clinical practices. For the food industry, deploying such phages could revolutionize contamination control by eliminating pathogens while stimulating subtle immune enhancement upon ingestion, potentially fortifying mucosal defenses. In clinical settings, these phages might complement existing antimicrobial regimes, especially in immunocompromised patients, by activating host defenses in tandem with bacterial clearance.

The discovery also invites a new paradigm where bacteriophage therapy could be tailored to modulate immune responses selectively. By engineering phages like JEP7 and PBC2, scientists might customize cytokine profiles to treat autoimmune diseases, chronic inflammation, or even to boost vaccine efficacy. This versatility elevates bacteriophages from mere bacterial killers to sophisticated immunotherapeutic platforms.

Yet, with exciting possibilities come challenges and unknowns. The long-term immunological consequences of sustained phage exposure remain to be fully elucidated. Could persistent cytokine induction lead to undesired inflammation or immune exhaustion? The current study provides a crucial first step but underscores the necessity for extended in vivo studies and clinical trials to map these dynamics comprehensively.

In summary, the research led by Jung and colleagues represents a landmark in bacteriophage science, merging microbiology and immunology to uncover how phages JEP7 and PBC2 can address foodborne pathogens while strategically engaging mammalian immune cells. This dual-action profile heralds a new frontier in phage therapy with profound implications for public health, food safety, and immunotherapy.

As antimicrobial resistance escalates into a global crisis, novel interventions like bacteriophage-based immune modulators become invaluable. The intricate dance between JEP7 and PBC2 phages and mammalian cytokines offers a promising path forward, where microbial predators serve as allies in augmenting human immunity.

Future research will undoubtedly expand on this foundation, exploring additional phage types, refining delivery methods, and decoding the complex immunological networks influenced by phage contact. The convergence of synthetic biology, immunology, and microbiology promises to translate these discoveries into practical interventions that may one day redefine how we approach infectious diseases and immune-related conditions.

Ultimately, the revelation that bacteriophages are more than mere bacterial killers but also immune system influencers marks a transformative step in biomedical science. The remarkable capabilities of JEP7 and PBC2 exemplify the untapped potential lurking within the virosphere—offering hope, innovation, and new weapons in humanity’s fight against microbial threats.

Subject of Research: Interaction of bacteriophages JEP7 and PBC2 with foodborne pathogens and their elicitation of cytokine responses in mammalian cells

Article Title: Bacteriophages JEP7 and PBC2, which target foodborne pathogens, elicit cytokine responses in mammalian cells

Article References:
Jung, Y., Kim, J., Lee, JH. et al. Bacteriophages JEP7 and PBC2, which target foodborne pathogens, elicit cytokine responses in mammalian cells. Food Sci Biotechnol (2025). https://doi.org/10.1007/s10068-025-02042-3

Image Credits: AI Generated

DOI: 26 November 2025